All In Biotech

Drug Trial Radar · NCT04363164

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 19, 2020

Primary completion

Jul 2027

Study completion Jul 2028

Sponsor

Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
Apr 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

Conditions

  • Castration Resistant Metastatic Prostate Cancer

Interventions

  • Testosterone cypionateDrug

    Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.

  • EnzalutamideDrug

    Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.

  • Testosterone enanthateDrug

    Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical or Radiographic Progression free survivalTime frame: Up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD)

    San Diego, California · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana-Faber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • University of Washington/Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.